{"id":111589,"date":"2026-08-03T17:13:03","date_gmt":"2026-08-03T17:13:03","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/"},"modified":"2026-08-03T17:13:03","modified_gmt":"2026-08-03T17:13:03","slug":"esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/","title":{"rendered":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\">New York, USA, Aug.  03, 2026  (GLOBE NEWSWIRE) &#8212; <b>Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight<\/b><\/p>\n<p align=\"justify\"><b><i>The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering cytotoxic agents directly to tumor cells with greater precision.<\/i><\/b><\/p>\n<p align=\"justify\">Recently published Esophageal Cancer Market Insights report includes a comprehensive understanding of current treatment practices, esophageal cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/p>\n<p align=\"justify\"><b>Esophageal Cancer Market Summary<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">The market size for esophageal cancer was found to be <b>USD 1.3 billion<\/b> in the 7MM in 2025.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The United States accounted for the largest esophageal cancer treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The total incident cases of esophageal cancer in the 7MM were approximately <b>79,000<\/b> in 2025.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Key esophageal cancer companies, including <b>Zymeworks, Jazz Pharmaceuticals, Amgen, AbbVie, Merck, Daiichi Sankyo, Eisai, Pfizer, Macrogenics, I-Mab, ABL Bio, <\/b>and others, are actively working on innovative esophageal cancer drugs.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Some of the key esophageal cancer therapies in clinical trials include <b>Zanidatamab, Bemarituzumab, Telisotuzumab Adizutecan (Temab-A), Ifinatamab deruxtecan (MK-2400), Lenvatinib (LENVIMA), PF-08046033, MGC026, Ragistomig<\/b>, and others. These novel esophageal cancer therapies are anticipated to enter the esophageal cancer market in the forecast period and are expected to change the market.<\/li>\n<\/ul>\n<p align=\"justify\">Discover esophageal cancer therapeutics market growth opportunities @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6ubyzvHDw9BwbmwW4NK2XaEIoFNQIk280QbYFJKZzftMp02lSb4nHP7dsxKNCr6P-EnxEzfcRFkbS26xMw9rn0xY2dzYv7TtfGABgVcJlV-RCak_qNEaHpgrx2FdtfVofv_iYHh_Lo0OUO3eJ0nUzjBCk0CMqn-GWE-NgXIedTfLUAtu3QuaLDgkPezXyZPBODlG4DeVgM-yDjxf45EqoGBhs5hSXUCsLv7D3JSyON3fPvBu7hRf1-ls5nsFFipPr3YeOOQ1rpF4fGVz_vV2Z0aA-UyMhwRPNYxFk75ScO5VNe3aNYbNUDDi362SeCcc\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>https:\/\/www.delveinsight.com\/report-store\/esophageal-cancer-market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Key Factors Driving the Growth of the Esophageal Cancer Market\u00a0<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><b>Rising Incidence of Esophageal Cancer: <\/b>The increasing prevalence of esophageal cancer, particularly esophageal adenocarcinoma and squamous cell carcinoma, is a primary driver of market growth. Factors such as aging populations, obesity, gastroesophageal reflux disease (GERD), tobacco use, and alcohol consumption continue to contribute to the growing disease burden.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Advancements in Multimodal Treatment Approaches:<\/b> The current treatment approach for esophageal cancer typically combines surgery, chemotherapy, radiation therapy, and, more recently, immunotherapy. Advances in perioperative and neoadjuvant treatment strategies have contributed to improved patient survival, while individualized treatment plans based on tumor stage and histological subtype continue to enhance disease management and drive growth in the esophageal cancer market.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Emergence of Immunotherapy and Targeted Therapies:<\/b> The advent of immune checkpoint inhibitors, including Pembrolizumab (<b>KEYTRUDA<\/b>), Nivolumab (<b>OPDIVO<\/b>), Tislelizumab (<b>TEVIMBRA<\/b>), and Durvalumab (<b>IMFINZI<\/b>), has reshaped the treatment paradigm for advanced and metastatic disease by delivering meaningful improvements in patient survival. At the same time, targeted therapies such as Ramucirumab (<b>CYRAMZA<\/b>) and Larotrectinib (<b>VITRAKVI<\/b>) are broadening therapeutic opportunities for patients with specific biomarker-defined profiles.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Growing Focus on Precision Medicine and Biomarker-Driven Therapies:<\/b> Recent progress in molecular diagnostics has improved the detection of actionable genetic alterations, supporting the advancement of targeted treatment strategies. Biomarker-guided therapies, such as those directed at HER2 and NTRK, are playing an increasingly important role in treatment selection, enhancing clinical outcomes and accelerating the adoption of personalized medicine for esophageal cancer.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Robust Pipeline of Novel Therapeutics:<\/b> A strong pipeline of investigational drugs, including <b>Zanidatamab <\/b>(Zymeworks\/Jazz Pharmaceuticals), <b>Bemarituzumab <\/b>(Amgen), <b>Telisotuzumab Adizutecan (Temab-A)<\/b> (AbbVie), <b>Ifinatamab deruxtecan (MK-2400)<\/b> (Merck\/Daiichi Sankyo), <b>Lenvatinib (LENVIMA)<\/b> (Merck\/Eisai), <b>PF-08046033<\/b> (Pfizer), <b>MGC026 <\/b>(Macrogenics), <b>Ragistomig <\/b>(I-Mab\/ABL Bio), and others is expected to reshape the treatment landscape. Continuous clinical development is attracting investments and expanding future market potential.<\/li>\n<\/ul>\n<p><\/p>\n<p align=\"justify\"><i>Aparna Thakur, project manager of forecasting at DelveInsight, said that the emerging therapies, including HER2-targeted agents such as Zanidatamab, FGFR2b-targeted therapies such as Bemarituzumab, and antibody-drug conjugates like Telisotuzumab adizutecan (Temab-A), are expected to witness gradual but steady uptake over the forecast period. Their adoption will largely depend on clinical trial outcomes, regulatory approvals, and the expansion of biomarker testing to identify eligible patient populations.<\/i><\/p>\n<p align=\"justify\"><b>Esophageal Cancer Market Analysis<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Systemic therapy plays a central role in the management of esophageal cancer by delivering medications through the bloodstream to target cancer cells throughout the body. The major systemic treatment approaches include <b>chemotherapy, targeted therapies, and immunotherapies<\/b>.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Among targeted therapies, <b>trastuzumab (HERCEPTIN\/OGIVRI)<\/b> is used in combination with chemotherapy as a first-line treatment for patients with metastatic esophageal adenocarcinoma.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Trastuzumab deruxtecan (ENHERTU)<\/b> is also approved for first-line treatment in this setting. For patients with advanced gastroesophageal or gastroesophageal junction adenocarcinoma whose disease has progressed following initial therapy, <b>ramucirumab (CYRAMZA)<\/b> combined with paclitaxel represents an established treatment option.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Immunotherapy has significantly broadened the therapeutic landscape of esophageal cancer. PD-1\/PD-L1 checkpoint inhibitors such as <b>pembrolizumab (KEYTRUDA) and nivolumab (OPDIVO) <\/b>have gained regulatory approval, while additional immune-targeted agents, including <b>ipilimumab (YERVOY), tislelizumab-jsgr (TEVIMBRA), and zolbetuximab-clzb (VYLOY),<\/b> further expand the available treatment arsenal.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The esophageal cancer pipeline continues to evolve, with several promising candidates under clinical development. Notable investigational therapies include <b>Zanidatamab<\/b> (Zymeworks\/Jazz Pharmaceuticals), <b>Bemarituzumab <\/b>(Amgen), <b>Telisotuzumab Adizutecan (Temab-A)<\/b> (AbbVie), <b>Ifinatamab deruxtecan (MK-2400)<\/b> (Merck\/Daiichi Sankyo), <b>Lenvatinib (LENVIMA)<\/b> (Merck\/Eisai), <b>PF-08046033<\/b> (Pfizer), <b>MGC026 <\/b>(Macrogenics), <b>Ragistomig <\/b>(I-Mab\/ABL Bio), and others, alongside several other emerging therapies that have the potential to reshape future treatment paradigms.<\/li>\n<\/ul>\n<p align=\"justify\">Learn more about disease-modifying therapies for esophageal cancer @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RJog7rw0zNQ1xASkcG5YLhoTFmQywhakJRXU-L7vfEUSIhf0hNSfqfSYPUfnIIUthVa9n2EstOaTMVahQnUcew8gXWts3eCSROmQb2TRiRienpp7thqItNdDUuyYnXUpr4GdcwUXq7QCMO13zjlMmJItqzSZxrTUn74wHPvSChV49N94w63a-J4ohbOYZDIdoW76f5Zqagcl9x5kcGwHIV6mzcTLOQGLkF6ECKs23fh8hMt4WpzpAUe8d1F6nbDYPK4L29Z-ZFiGRVkzB0KMiw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Esophageal Cancer Treatment Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Esophageal Cancer Competitive Landscape<\/b><\/p>\n<p align=\"justify\">Some of the esophageal cancer drugs under development include <b>Zanidatamab <\/b>(Zymeworks\/Jazz Pharmaceuticals), <b>Bemarituzumab <\/b>(Amgen), <b>Telisotuzumab Adizutecan (Temab-A)<\/b> (AbbVie), <b>Ifinatamab deruxtecan (MK-2400)<\/b> (Merck\/Daiichi Sankyo), <b>Lenvatinib (LENVIMA)<\/b> (Merck\/Eisai), <b>PF-08046033<\/b> (Pfizer), <b>MGC026 <\/b>(Macrogenics), <b>Ragistomig <\/b>(I-Mab\/ABL Bio), and others.<\/p>\n<p align=\"justify\"><b>Zymeworks\/Jazz Pharmaceuticals\u2019 Zanidatamab<\/b> is an advanced-stage investigational oncology therapy designed to target multiple HER2-expressing malignancies and has the potential to redefine treatment approaches across several cancer indications. The therapy has shown encouraging clinical efficacy in biliary tract cancer and gastroesophageal adenocarcinoma (GEA), with broader applicability anticipated in additional HER2-positive tumors. It has also been granted <b>Fast Track Designation (FTD)<\/b> for use in combination with standard chemotherapy as a first-line treatment for gastroesophageal adenocarcinoma. The ongoing <b>Phase III HERIZON-GEA-01<\/b> study is assessing zanidatamab alongside chemotherapy, with or without the PD-1 inhibitor <b>tislelizumab<\/b>, as an initial treatment option for patients with metastatic HER2-positive GEA.<\/p>\n<p align=\"justify\"><b>Merck\/Eisai\u2019s Lenvatinib<\/b> is an oral multi-targeted kinase inhibitor that blocks signaling through vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), thereby suppressing tumor angiogenesis. In addition to VEGF receptors, it inhibits several other kinases involved in cancer development and progression, including fibroblast growth factor receptors (FGFR1\u20134), platelet-derived growth factor receptor alpha (PDGFR\u03b1), KIT, and RET. The therapy is being co-developed with <b>KEYTRUDA<\/b>, and the combination is currently under evaluation in a <b>Phase III<\/b> clinical trial for metastatic esophageal carcinoma. Development of LENVIMA is being carried out through a collaboration with Eisai.<\/p>\n<p align=\"justify\"><b>AbbVie\u2019s Telisotuzumab adizutecan<\/b> is an investigational antibody-drug conjugate (ADC) that targets c-Met, a receptor commonly overexpressed in various solid malignancies. The therapy is currently being investigated across multiple tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastroesophageal adenocarcinoma.<\/p>\n<p align=\"justify\"><b>Merck\/Daiichi Sankyo\u2019s Ifinatamab deruxtecan<\/b> is a novel investigational antibody-drug conjugate composed of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. The candidate is being jointly developed through a collaboration with Daiichi Sankyo.<\/p>\n<p align=\"justify\">The anticipated launch of these emerging esophageal cancer therapies are poised to transform the esophageal cancer market landscape in the coming years. As these cutting-edge esophageal cancer therapies continue to mature and gain regulatory approval, they are expected to reshape the esophageal cancer market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n<p align=\"justify\">To know more about emerging esophageal cancer therapies, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RJog7rw0zNQ1xASkcG5YLmMPCgYikFcNeXQYfMYz26zcw1nG9bYkKRvKeIQCn545vFckuV8s5ViReUqEFTlPIr5c-Gt-IWPTLDrzTYPlli2CcxnRUCprLNcOuCdp8txIF76MUWrWPLlr87ZWcCt8Jjnm5W4n1f1tExXTyVwOu3DBhJQf49oQBGPfMf1BDPd-dpwsUtqRz7rrEbSrDREo8HrOLMVpdkpkvJcXzQWZlLRUcrV2Zl6N_Ex45ijr-aif\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Esophageal Cancer Medication<\/b><\/a><\/p>\n<p align=\"justify\"><b>Recent Developments in the Esophageal Cancer Market<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">In <b>November 2025, <\/b>the FDA approved durvalumab (IMFINZI, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>November 2025,<\/b> Pembrolizumab (KEYTRUDA) in combination with chemotherapy showed sustained long-term survival benefit in advanced esophageal cancer, with 5-year follow-up data from the Phase III KEYNOTE-590 study confirming improved overall survival and progression-free survival versus chemotherapy alone.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>March 2025,<\/b> Tislelizumab (TEVIMBRA) received FDA approval in combination with chemotherapy for first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma (ESCC) with PD-L1 expression, marking an important addition to frontline immunotherapy options.<\/li>\n<\/ul>\n<p align=\"justify\"><b>Esophageal Cancer Epidemiology Segmentation<\/b><\/p>\n<p align=\"justify\">The esophageal cancer epidemiology section provides insights into the historical and current esophageal cancer patient pool and forecasted trends for the leading markets. It has been observed that the incidence of non-squamous cell esophageal cancer is higher (~<b>14,000<\/b>) as compared to squamous cell esophageal cancer (~<b>8,000<\/b>) in the United States.<\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IcPJr9y48WGJbegOwQbLK0Kpv_o4TSh2zm6V0MOsd3eAx9y3U56dTJRY1BLej3fh2xM1gjsilN4Le3gOdYAIXrG93xdPaKuXFEvvjtbpA9qjuHjHnbQTC5caE3tyjkHvJpx7wr7iaVmx8M5ij6JlP6Se7iV2EhVQlCWn02mUyFW5h7-yy7ARR4vcEJuWXnWRfZ9wQWOFLE1b88zBJxIwuPuGzoqCuXEkqbErowdREDP-31hD-Jx-m5gTmXdX0j_t\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>esophageal cancer market report<\/b><\/a> proffers epidemiological analysis for the study period 2022\u20132036 in the leading markets segmented into:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Total Diagnosed Incident Cases of Esophageal Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Histology-specific Cases of Esophageal Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Gender-specific Cases of Esophageal Cancer\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Age-specific Cases of Esophageal Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Mutation-specific Cases of Esophageal Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Total Stage-specific Cases of Esophageal Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Line wise Treated Cases of Esophageal Cancer<\/li>\n<\/ul>\n<p align=\"justify\">Download the report to understand the future of esophageal cancer treatment @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RJog7rw0zNQ1xASkcG5YLhoTFmQywhakJRXU-L7vfEUfwpf45Z0gtPalvZumJWwrS6dp4CALq8zykxn6h4jIQQ7FDj6-zErUR7THqH_mv9pMpmMzvfxn1-bWdJ6FWF82E6gCv1RDWony77YoGqI8elsQmBlX9wRZWkfnl5qq0ZjqHV0WfTUMFWdh2Og9J6vFQEULMqV03X6ds_UtFDK48Vq9x_MO17mlY6YdR_PioHkKlufcmvMe4iaEDSfo4cUCNNcKR9HPcQnsSjMp-7E-qg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Esophageal Cancer Treatment Options<\/b><\/a><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Esophageal Cancer Market Report Metrics<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Details<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Study Period<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2022\u20132036<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Esophageal Cancer Market Report Coverage<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Esophageal Cancer Market CAGR\u00a0<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Esophageal Cancer Market Size in 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">USD 1.3 Billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Esophageal Cancer Companies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Zymeworks, Jazz Pharmaceuticals, Amgen, AbbVie, Merck, Daiichi Sankyo, Eisai, Pfizer, Macrogenics, I-Mab, ABL Bio, BeiGene, AstraZeneca, and others<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Esophageal Cancer Therapies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Zanidatamab, Bemarituzumab, Telisotuzumab Adizutecan (Temab-A), Ifinatamab deruxtecan (MK-2400), Lenvatinib (LENVIMA), PF-08046033, MGC026, Ragistomig, TEVIMBRA, IMFINZI, and others<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Scope of the <\/b><b>Esophageal Cancer<\/b><b> Market Report<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Esophageal Cancer Patient Population Forecast<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Esophageal Cancer Therapeutics Market Size<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Esophageal Cancer Pipeline Analysis<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Esophageal Cancer Market Size and Trends<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Esophageal Cancer Market Opportunity<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Esophageal Cancer Market Unmet Needs<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">KOL\u2019s Views on Esophageal Cancer<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Esophageal Cancer Market Access and Reimbursement<\/li>\n<\/ul>\n<p align=\"justify\">Discover more about next-generation esophageal cancer drugs @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RJog7rw0zNQ1xASkcG5YLiqtxEKcZpXFqFbbHMUXvhXIBKr6295et_As45NdR74AgutyNu61mrM1jJZSFrxX6Kad3YcAz2ddp5HRAjBarmA4oUkHYarAwk_qQEAp_1vGL8I2287w1uYnNN0JhaJgqPTPhnb8oewD9U4JzTdxZHevXYAl6OskOIileuJuVILfzkeRRB8yDeYhzm14oQeBCr1eyoec0c8Q2qZix8Rj35fOp6Mp5cJWDK_3gqZPH5j7tqaYgc_r6QNffoNQbhALwA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Esophageal Cancer Clinical Trials<\/b><\/a><\/p>\n<p align=\"justify\"><b>Table of Contents<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">1<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Esophageal Cancer Market Key Insights<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Esophageal Cancer Market Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Events<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Market Forecast Methodology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Esophageal Cancer Market Overview at a Glance<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Share (%) Distribution of Esophageal Cancer By Therapies in the 7MM, in 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Share (%) Distribution of Esophageal Cancer By Therapies in the 7MM, in 2036<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Disease Background and Overview of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Types<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Symptoms<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Causes<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Pathophysiology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Diagnosis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment Guidelines of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Patient Population of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Assumptions and Rationale<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Incident Cases of Esophageal Cancer in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Diagnosed Incident Cases of Esophageal Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Histology-specific Cases of Esophageal Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Gender-specific Cases of Esophageal Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Age-specific Cases of Esophageal Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Mutation-specific Cases of Esophageal Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Stage-specific Cases of Esophageal Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Line-wise Treated Cases of Esophageal Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">10<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Patient Journey of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Marketed Esophageal Cancer Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Marketed Competitive Landscape of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Entrectinib (ROZLYTREK): Eli Lilly and Company<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Drug Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Regulatory Milestones<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Developmental Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Summary of Pivotal Trials<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.5.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trial Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Entrectinib (ROZLYTREK): Eli Lilly and Company<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Tislelizumab (TEVIMBRA): BeiGene<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \"><i>List to be continued in the report\u2026<\/i><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Emerging Esophageal Cancer Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Emerging Competitive Landscape of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Zanidatamab: Jazz Pharmaceuticals\/Zymeworks<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Drug Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Developmental Activity<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trials Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Telisotuzumab adizutecan: AbbVie<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \"><i>List to be continued in the report\u2026<\/i><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Esophageal Cancer Market: 7MM Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Outlook of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Market Forecast Assumptions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Conjoint Analysis of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Esophageal Cancer in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Esophageal Cancer by Therapies in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States Esophageal Cancer Market\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Esophageal Cancer in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of Esophageal Cancer by Therapies in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK Esophageal Cancer Market\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan Esophageal Cancer Market\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">14<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Unmet Needs of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">15<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">SWOT Analysis of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">16<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">KOL Views of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Access and Reimbursement of Esophageal Cancer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Summary and comparison of Market Access and Pricing Policy Developments in 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Access and Reimbursement of Esophageal Cancer Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">18<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Bibliography<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">19<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Esophageal Cancer Market Report Methodology<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RJog7rw0zNQ1xASkcG5YLiqtxEKcZpXFqFbbHMUXvhUYH-qJFh7k7sOL7lBCmROtKK4yix07Ydi0G0CZf4h5kKcWFQ43sAPCSBgxvKNcvCQlBjphpX7Dw6F_CmkkeAluwmiAJjz1ljGhWSAxJpcKPOSfBLAn9Uq8GnWMo0qcpv11q1We0-FRrhXNMlCRQsZTD2EOxDjq02mbG3QsM4RZbxQR2CXeS55SBTfRx1pSeHLpIHG-kCUFF7gS0ciuUlu0d64Pxh4MDlIF_XrSI1csoEDfXmTJ7RR7uNxY_p-BWeU=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Esophageal Cancer Clinical Trial Analysis\u00a0<\/b><\/a><\/p>\n<p align=\"justify\"><b>Esophageal Cancer Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key esophageal cancer companies, including <b>OncoTherapy Science, Inc., Shionogi &amp; Co., Oncolys BioPharma Inc., Lyvgen Biopharma, Adlai Nortye Biopharma, NovaRock Biotherapeutics, Genmab, Genentech, Jiangsu HengRui Medicine, Taiho Pharmaceutical, Mirati Therapeutics, Boehringer Ingelheim, Suzhou Zelgen Biopharmaceuticals, Active Biotech, NeoTX Therapeutics, Rakuten Medical, HLB, CDR-Life, Schrodinger, BioSyngen, Guangzhou Bio-gene Technology, GO Therapeutics, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KHcrmuoorcw8G7yhY3zuDQ1ScccJmo7mtx8_ipYMbnDJ6z0kZDaoj51xt1WSWHnfxuO9h6fY57rIR83yivxsuaUH96MZVX5nZoS985BYc6KQUJkKnKi1D4jR8Tpr5lPTxw3KJpPjrgL2vfmYfFCeMbFoI6G-08BGwzct0Gt0MYlKmsf76UerJvQxyME5YC7K4GZ4frtaWwFGmbkjzgmtY-NKcOBowip6a-a6BIf0nE-tGmE-1LUcZQ9uO5jVOwg42WJNI1E9b1gekg_97kBNgCoh4nw_OSZ1jax3OyvQWNs=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastroesophageal Reflux Disease Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast \u2013 2036<\/b> report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key GERD companies including <b>Phathom Pharmaceuticals, Inc., Microbiome Health Sciences, Takeda, Braintree Laboratories, AstraZeneca, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KHcrmuoorcw8G7yhY3zuDQ1ScccJmo7mtx8_ipYMbnCkiJi0CVMZiRLG0rMLfi_SK6N5ijdG43We6mu41qtNvPzToWaq0syNCxs5uuF8bGXShjK96er6wSLSoMNw5A2yr_IQZC9fNF9lTihTz5VBp9rk77LyeDrcEyd-o8tuPhpp9DTML67MRQs2woSxFut0A_8O1rHHqSlBScXRWVLi1FYFNWtld0Hko0eCpl1uQjtOAHa_Gwmto8KCtcs2BiefK511v1g0HMuFyCcBzMctNgG4T7uxEFWLdNlt5DoLVNUanxYcvS57yWpcdwkjFD3hP9Eab_e535AwRmeW52NrXA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Gastroesophageal Reflux Disease Clinical Trial Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>Gastroesophageal Reflux Disease Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GERD companies, including <b>Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jOKFmEERnn6eZ8rL8gV2TOov4z0lLce66TuP9DF-e9crpJc-kviFbbPq6-tukxypcK0Lm2SAZM9hrVPEPsttRVxEl2kS3cc4BZj3yqJlRs6z2A8ajo3ZZ2fYur7uNU1-btWR9E-2TT-YP_HSKwnFBmC4u6XvBGlWq_7raO8ErwEF4nOOtKLSd4WWT6CFvFJDrTGzrJyykWWhcaj3rFQl7yBwhYaUBa9v71vl5NuNbu76PaJoIN_2VJxa01pFpM3eZfdRmulWoRleD0YNudxyBw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Head and Neck Cancer Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast <\/b><b>\u2013 2036 <\/b>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HNC companies, including <b>CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp &amp; Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company<\/b><b>, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jOKFmEERnn6eZ8rL8gV2TOov4z0lLce66TuP9DF-e9dcDPpwZ7g4EZlFW3yO0FuwxG3of0vCXvs60ZnEnIRJjVtJcnLZtasimk34CcIamw68a0cPK_lg55lU1bsEKfyf1pi725NUctWGJD8Q-I9APNqxnQIhO-BB7J4bB9I59o8-Za8-snzFDVstDuYX2AbMqDCK_WMuIqjDO5kHVcJoPobSgl9QS4Lwg84r6qnore6P52hgz1su0D2nBZAynOxG9ZPokJZRYXZBObfA1rJq4bbPpsJUL-6tK8o3pLb2yRw=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Head and Neck Cancer Clinical Trial Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>Head and Neck Cancer Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HNC companies, including <b>Merus, Bicara Therapeutics, Kura Oncology, Inc., Theriva Biologics, Nykode Therapeutics ASA, Cue Biopharma, BioNTech SE, Exelixis, AstraZeneca, Johnson &amp; Johnson, Intragel, AbbVie, IOVANCE Biotherapeutics, Immutep Limited, Repertoire Immune Medicines, Pyxis Oncology, Inc., ALX Oncology, iTeos Therapeutics, AVEO Oncology, Akeso Biopharma, Coherus BioSciences, Inc., Flamingo Therapeutics, Adlai Nortye Ltd, Hibercell Inc., Elpiscience Biopharmaceuticals, KSQ Therapeutics, Transgene, <\/b>and others.<\/p>\n<p align=\"justify\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<pre\/><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmExZTQ0YzUtOTMwYy00ZTMzLTk0NTctYTc0NWNhYTZjMWJkLTEyMDQ5MzgtMjAyNi0wOC0wMy1lbg==\/tiny\/DelveInsight-Business-Research.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) &#8212; Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":111590,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/dbcddd65-71dd-4559-8875-ae89ac4f96db","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-111589","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Gias Ul Hassan\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan - Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight\" \/>\n\t\t<meta property=\"og:description\" content=\"New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-08-03T17:13:03+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-03T17:13:03+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight\" \/>\n\t\t<meta name=\"twitter:description\" content=\"New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#blogposting\",\"name\":\"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight\",\"headline\":\"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight\",\"author\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ml.globenewswire.com\\\/Resource\\\/Download\\\/dbcddd65-71dd-4559-8875-ae89ac4f96db\"},\"datePublished\":\"2026-08-03T17:13:03+00:00\",\"dateModified\":\"2026-08-03T17:13:03+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#webpage\"},\"articleSection\":\"GlobeNewswire\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"name\":\"GlobeNewswire\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"position\":2,\"name\":\"GlobeNewswire\",\"item\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#listItem\",\"name\":\"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#listItem\",\"position\":3,\"name\":\"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/category\\\/globenewswire\\\/#listItem\",\"name\":\"GlobeNewswire\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\",\"name\":\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan\",\"description\":\"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/Pakistan-News.png\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#organizationLogo\",\"width\":191,\"height\":78,\"caption\":\"Pakistan-News\"},\"image\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/\",\"name\":\"Gias Ul Hassan\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#webpage\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/\",\"name\":\"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight\",\"description\":\"New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/author\\\/giasulhassan\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/ml.globenewswire.com\\\/Resource\\\/Download\\\/dbcddd65-71dd-4559-8875-ae89ac4f96db\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#mainImage\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\\\/#mainImage\"},\"datePublished\":\"2026-08-03T17:13:03+00:00\",\"dateModified\":\"2026-08-03T17:13:03+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#website\",\"url\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/\",\"name\":\"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan\",\"description\":\"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/pakistaninewspaperlist.com\\\/news\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight","description":"New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates","canonical_url":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#blogposting","name":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight","headline":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight","author":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"publisher":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/dbcddd65-71dd-4559-8875-ae89ac4f96db"},"datePublished":"2026-08-03T17:13:03+00:00","dateModified":"2026-08-03T17:13:03+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#webpage"},"isPartOf":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#webpage"},"articleSection":"GlobeNewswire"},{"@type":"BreadcrumbList","@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news#listItem","position":1,"name":"Home","item":"https:\/\/pakistaninewspaperlist.com\/news","nextItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","name":"GlobeNewswire"}},{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","position":2,"name":"GlobeNewswire","item":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/","nextItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#listItem","name":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight"},"previousItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#listItem","position":3,"name":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight","previousItem":{"@type":"ListItem","@id":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/#listItem","name":"GlobeNewswire"}}]},{"@type":"Organization","@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization","name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan","description":"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","url":"https:\/\/pakistaninewspaperlist.com\/news\/","logo":{"@type":"ImageObject","url":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#organizationLogo","width":191,"height":78,"caption":"Pakistan-News"},"image":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author","url":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/","name":"Gias Ul Hassan"},{"@type":"WebPage","@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#webpage","url":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/","name":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight","description":"New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#website"},"breadcrumb":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#breadcrumblist"},"author":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"creator":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/author\/giasulhassan\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/dbcddd65-71dd-4559-8875-ae89ac4f96db","@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#mainImage"},"primaryImageOfPage":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/#mainImage"},"datePublished":"2026-08-03T17:13:03+00:00","dateModified":"2026-08-03T17:13:03+00:00"},{"@type":"WebSite","@id":"https:\/\/pakistaninewspaperlist.com\/news\/#website","url":"https:\/\/pakistaninewspaperlist.com\/news\/","name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan","description":"Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","inLanguage":"en-US","publisher":{"@id":"https:\/\/pakistaninewspaperlist.com\/news\/#organization"}}]},"og:locale":"en_US","og:site_name":"Pakistan Daily  News Updates- Complete Zila News Updates all over Pakistan - Pakistan News, Daily Urdu News, Local News Pakistan, All District News Pakistan","og:type":"article","og:title":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight","og:description":"New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates","og:url":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/","og:image":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","og:image:secure_url":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png","article:published_time":"2026-08-03T17:13:03+00:00","article:modified_time":"2026-08-03T17:13:03+00:00","twitter:card":"summary_large_image","twitter:title":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight","twitter:description":"New York, USA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates","twitter:image":"https:\/\/pakistaninewspaperlist.com\/news\/wp-content\/uploads\/2023\/08\/Pakistan-News.png"},"aioseo_meta_data":[],"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/pakistaninewspaperlist.com\/news\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/\" title=\"GlobeNewswire\">GlobeNewswire<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tEsophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/pakistaninewspaperlist.com\/news"},{"label":"GlobeNewswire","link":"https:\/\/pakistaninewspaperlist.com\/news\/category\/globenewswire\/"},{"label":"Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026\u20132036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight","link":"https:\/\/pakistaninewspaperlist.com\/news\/esophageal-cancer-market-to-accelerate-at-a-cagr-of-6-during-the-forecast-period-2026-2036-driven-by-the-advancements-in-targeted-and-immunotherapy-treatments-delveinsight\/"}],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/111589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=111589"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/111589\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/111590"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=111589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=111589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=111589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}